Pharmaceutical Partnerships with AI Drug Discovery

Explore the dynamic intersection of pharmaceuticals and artificial intelligence, where innovation is reshaping the landscape of drug discovery. With over 250 global Digital Health ventures, including Pharmaceutical partnerships with AI ventures, embracing the power of AI, witness the transformative journey as we delve into the relationships between pharmaceutical leaders and these trailblazing ventures. Uncover the strategic partnerships shaping the future of precision medicine and witness the impact on global healthcare outcomes. Discover the dynamic intersection of AI drug discovery, venture capital, and pharmaceutical innovation.

HealthTech Alpha, a proprietary solution by Galen Growth and the world’s leading Digital Health private market data, intel, and insights platform, powers this mini report! Mini reports and Featured Flashcards can be found on HealthTech Alpha’s Research page.

Highlights

Explore in this mini report the dynamic intersection between pharmaceuticals and artificial intelligence, uncovering key highlights, including Pharmaceutical partnerships with AI ventures:

  • AI Funding Surge: Over $13.9B invested in AI drug discovery in the last 5 years, with 2023 witnessing a monumental $6.8B surge.
  • Global Collaboration: North America leads with 105 ventures, followed by Europe (80) and Asia Pacific (55), reflecting universal commitment.
  • Pharma-AI Partnerships: 91 pharma giants formed 900+ partnerships; Pfizer, Bayer, and Eli Lilly at the forefront with 13 each.
  • Research Focus: Cancer research dominates with 45 partnerships, showcasing industry dedication to tackling critical medical challenges.
  • Pinnacle Ventures: PathAI, XtalPi, Benchling, DNAnexus, and Artios Pharma identified as mature players, leading in innovation and partnerships.

Featured Companies

The “Pharmaceutical Partnerships with AI Drug Discovery” mini report includes the following companies:

Pfizer, Bayer, Lilly, Merck KGaA, Bristol-Myers Squibb, Sanofi, Johnson & Johnson Innovative Medicine, AstraZeneca, Boehringer Ingelheim, Roche, PathAI, XtalPi, Benchling, DNAnexus, Artios Pharma

Missed our last report?

Get access to HealthTech Alpha and read our Pharmaceutical Digital Health Innovation Index 2023

About our Premium Reports

Our Premium Reports are specialized reports that are only available to active users with HealthTech Alpha Pro and HealthTech Alpha Enterprise accounts and are provided at no additional cost.

Source of Data

Galen Growth’s proprietary platform, HealthTech Alpha, provides the data source for this report. Corporate Business Development, Business Intelligence, and Digital Health Partnership teams worldwide prefer HealthTech Alpha, the world’s most-trusted Digital Health data, intel, and insights platform. Visit https://www.healthtechalpha.com to learn more about our data or https://www.galengrowth.com research for our reports.

Our Mission

Founded in 2016 by Digital Health experts, Galen Growth empowers global Fortune 500 companies, institutional investors, and promising Digital Health ventures to fast track their digital health strategy to create significant financial and social values. To find out more, visit https://www.galengrowth.com

ECOSYSTEM OVERVIEW: 6 pages, 5 charts, 5 tables
PARTNERSHIPS: 5 pages, 3 charts, 3 table
PHARMA PARTNERSHIP DEEP DIVE: 2 pages, 2 charts, 2 tables
TOP VENTURES: 1 page, 1 table
RECENT CLINICAL EVIDENCE: 1 pages, 1 table
KEY INFORMATION
ABOUT GALEN GROWTH

Free

BASIC

  • Download the report headlines
  • Access to limited data in HealthTech Alpha
Free
View
Recommended

PRO

  • Sign up now to download all premium research
  • Access and download all data in HealthTech Alpha
$ 385 /Month
Pro
Custom Solution

Enterprise

  • Get full access to unmatched premium research for your organization
  • Additional collaboration features to take your team's research and collaboration to the next level
Let's Talk
Contact Us

© Galen Growth 2024

Overview

Category

Stage

Total Funding

GGA Score

powered by